Pharma industry, the next challenge
Improving clinical and economic value
A new economic framework for end-to-end management for pharmaceutical companies—one that starts in the R&D phase and delivers value to payors, patients, and shareholders in today’s health care system.
The traditional model for pharmaceutical commercialization—compound discovery, clinical trials, regulatory approval, promotional campaigns—worked for a long time but is under increasing pressure from stronger cost-containment measures and declining research productivity.
To remain competitive and financially successful, pharmaceutical companies should become more proactive in addressing both the economic and clinical value of products across the product life cycle. Companies should be able to demonstrate their value economically to patients and payors and to create more innovation around delivering economic value.
To achieve these objectives, pharma companies and health care systems are investing in new approaches like Comparative Clinical and Economic Value (CCEV™). These approaches can help distinguish the specific characteristics of a drug, medical device, or intervention and then for each distinctive feature more closely measure its economic value (including reduced physician time, decreased bed days, smaller diagnostic costs, and lower requirements for additional drugs).
CCEV™ enables companies to focus their efforts on creating value for patients and payors and enables companies to apply economic value-based thinking across the entire development, commercialization, and health care delivery process.
As used in this document, "Monitor Deloitte" means the Strategy practice of Deloitte Consulting LLP, a subsidiary of Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.